BioWorld

Oct. 28, 2010

Sequencing Star PacBio Gets Out IPO Window After Aegerion

The good news is that Pacific Biosciences Inc. raised a hefty $200 million in its initial public offering, pricing at the midpoint of its expected range and closing up on its first day of trading. (BioWorld Today) Read More

GTx Offering to Add $40M, Rebuild Reserves, Buy Time

'Here There be Dragons' Days of Genomics Drawing to Close

NewCo News: BMT Takes 'Shorter' Approach to Develop RNAi-Based Drugs

Other News To Note

Clinic Roundup

Earnings Roundup

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Feb. 4, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...